Tauriga Sciences Inc. Appoints Renowned New York City Based Dermatologist Steven Victor MD as Third Member of Company's Medical Advisory Board

        Print
| Source: Tauriga Sciences Inc

NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a life sciences company creating a diversified portfolio of medical technology assets, has today announced the appointment of Dr. Steven Victor ("Dr. Victor") as the third member of the Company's medical advisory board. As the Company continues to evaluate potentially lucrative opportunities in the life sciences space, including the recently announced Memorandum of Understanding ("MOU") with Constellation Diagnostics, Inc. ("Constellation"), Dr. Victor, President of ReGen Medical, has a vast knowledge base as a world renowned dermatologist and is of great importance to the Company. In addition, Dr. Victor's entrepreneurial business mind enhances the Company's access to potentially lucrative opportunities in the life sciences space. As the third member of the Company's medical advisory board, Dr. Victor will join Dr. Lawrence A. May ("Dr. May"), an internist with 35 years of clinical experience, and the Company's Chief Operating Officer, Dr. Stella M. Sung ("Dr. Sung"), an experienced biotech venture capitalist. The Company is working diligently to attract additional members to its Medical Advisory Board with the ultimate goal of securing five to seven outstanding members with the optimal balance of scientific and clinical expertise and relevant sector experience in medical devices, biopharmaceuticals, diagnostics and consumer health care.

Tauriga's CEO Seth M. Shaw commented, "The Company is fortunate to have attracted such a well respected and accomplished dermatologist as Dr. Steven Victor to its medical advisory board. As the Company plans on investing in the space on preventative oncology, specifically pertaining to skin cancer, management will consult closely with Dr. Victor and benefit from his exceptional knowledge of the medical field of dermatology."

Newly appointed Medical Advisory Board member Dr. Victor stated, "The management team of Tauriga genuinely impressed me and I look forward to assisting the Company in creating shareholder value. As a well established dermatologist in the New York City market, I look forward to advising the Company on both the development of Constellation Diagnostics and other potentially lucrative opportunities that may be accessible."

Please see below Bio for Steven Victor MD:

Dr. Victor earned his undergraduate degree from New York University ("NYU"), and his MD from the prestigious New York University Medical College. In subsequent years he has extended his affiliation with this learning institution through teaching appointments and continued support. In addition, teaching appointments to Beth Israel Medical Center ("Beth Israel") and Lenox Hill Hospital ("Lenox Hill") have significantly added to his experience as a teacher and a doctor. Running a post-graduate course in Cosmetic Dermatology from 1992 to 1998, he helped make that division of dermatology different from medical dermatology.

Other rewarding positions include his appointments as the consulting dermatologist for Elizabeth Arden, Clarins, Pierre Cardin, as well as Angio Medical Corporation, Medicis Pharmaceuticals, and the Orentreich Foundation for the Advancement of Science. In addition Dr. Victor has had the opportunity to give numerous newspaper, magazine and television interviews, and is honored to have been named one of New York Magazine's "Best Doctors in New York," Woodward and White's "Best Doctors in America," and Town & Country's "Best Cosmetic Surgeons." He has pioneered, perfected and delivered some of the most ground breaking and highly effective skin rejuvenation treatments that exist today. Beginning in 1982, he helped develop the first true cosmeceutical. In 1988, he introduced the first professional peeling formula to the aesthetician and plastic surgery worlds. In 2001, he formulated a full line of cosmeceutical treatments. Other highlights have included bringing Botox to Paris, and Restylane from Europe to the United States. In 1992 he was featured by the New York Times for bringing Mesotherapy to the United States. 

In 2002, his first book, "Ageless Beauty, A Dermatologist's Secrets to Looking Younger Without Surgery" was published. Today his practice continues to grow with both new patients and long-term patients for more than 30 years, many of them in the worlds of modeling, show business and society. These include a number of celebrities and household names.

http://www.victordermatologyandrejuvenation.com

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. ("the Company") is a life science company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address (www.taurigasciences.com).

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.

For more information please contact:

Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc.
www.taurigasciences.com
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: